Targeting Renal Purinergic Signaling for the Treatment of Lithium-induced NDI
靶向肾脏嘌呤信号传导治疗锂诱导的 NDI
基本信息
- 批准号:7931303
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-04-01 至 2014-03-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAdverse effectsAffectAgonistAmilorideAnxietyArgipressinBiologicalBiological ModelsBipolar DisorderBloodCardiovascular systemCell Culture TechniquesCellsChemosensitizationChronicClinicalClinical TrialsCoagulation ProcessCombined Modality TherapyConsciousCulture MediaDataDehydrationDevelopmentDrug Delivery SystemsDuct (organ) structureElderlyElectrolytesEquilibriumEvaluationEventFormulariesFreedomFunctional disorderFundingFutureGeneral PopulationGeneticGoalsHealthcareHypernatremiaHypovolemiaInfusion proceduresInjection of therapeutic agentInterventionIntoxicationInvestigationIraqKidneyKnock-outKnockout MiceKnowledgeLaboratoriesLifeLiquid substanceLithiumMajor Depressive DisorderMarinesMarketingMediatingMental DepressionMethodsMissionModalityModelingMolecularMorbidity - disease rateMusNatureNephrogenic Diabetes InsipidusNucleotidesOutcomeP2Y2 receptorPTGS2 genePathway interactionsPatientsPharmaceutical PreparationsPhysiologicalPlavixPlayPost-Traumatic Stress DisordersPrevalencePurinoceptorRattusReceptor GeneReplacement TherapyReportingResearchResistanceRiskRoleSafetyScreening procedureSignal TransductionSoldierStagingSubstance abuse problemSurveysSystemTechniquesTherapeuticTherapeutic AgentsTherapeutic UsesTissue SampleTissuesUrineV2 ReceptorsVasopressinsVeteransVietnamWarWaterWild Type MouseWorkabstractinganalogbaseclinical practiceclinically relevantclopidogreldesignextracellularfeedinghemodynamicshigh riskimprovedin vivoinfancyinhibitor/antagonistinnovationinsightmeetingsmortalitynovelolder patientoperationpreventpurinoceptor P2Y4receptorresearch studyresponsesocialsuccesssuicidal riskurinary
项目摘要
DESCRIPTION (provided by applicant):
6. Project Summary/Abstract Nephrogenic diabetes insipidus (NDI) due to lithium therapy for bipolar disorder is one of the major nephrological problems among Veterans. NDI is a debilitating condition with an elevated risk of morbidity and even mortality, especially in elderly Veterans. Currently used therapeutic modalities for NDI are encountered with varying degrees of success as well as side effects, including lithium intoxication. Refinement and/or replacement of the current side effect-prone therapies with new drugs based on an improved understanding of molecular pathophysiology of lithium-induced NDI should result in improved efficacy and fewer side effects. Research carried out by us during the current funding period provided significant insights into the potential role of purinergic signaling in the genesis of lithium-induced NDI. These are: (i) purinergic signaling may play a potential overarching role in balancing the effect of arginine vasopressin (AVP) on the urinary concentration mechanism; (ii) in lithium-induced NDI, purinergic signaling in the medullary collecting duct is sensitized and involves more than one subtype of P2Y receptors; and (iii) P2Y2 receptor gene knockout mice are significantly resistant to the development of lithium-induced NDI, suggesting the potential role of purinergic signaling in the genesis of lithium-induced NDI. Based on our novel and significant observations we hypothesize that a deeper understanding of the role of renal purinergic signaling in Li-induced NDI offers better therapeutic modalities. A new class of drugs that target purinergic signaling may improve the safety and/or efficacy of the current medications in combination therapies, or replace them in the treatment of Li-induced NDI. The specific objective of the project are: 1) to investigate the role of purinergic signaling in the development of Li-induced AVP resistance using P2Y2 receptor knockout and wild type mice; 2) to investigate the role of purinergic signaling in Li-induced AVP resistance of medullary collecting duct using primary cultures of mouse inner medullary collecting duct cells; and 3) to investigate the effect of amiloride and COX-2 inhibition on Li-induced NDI in a background of blunted purinergic signaling. To achieve our objectives we will use P2Y2 receptor knockout mice, rats and cell culture models, and employ molecular, functional, immunohistochemical and cell signaling techniques.
PUBLIC HEALTH RELEVANCE:
7. Project Narrative Post-traumatic stress disorder, often seen in Veterans, predisposes them to bipolar disorder. Currently there are more than 27 million Veterans, of which about 4% suffer from bipolar disorders. About 30% of bipolar Veterans receive lithium treatment, which is the drug of choice because of low suicidal risk in lithium treated patients. However, the therapeutic use of lithium is associated with a major side effect, called nephrogenic diabetes insipidus (NDI). NDI is associated with morbidity and even mortality, if not treated properly. Currently used medications for the treatment of NDI have side effects and may not be safe all patients. The observations made by us on the potential role of purinergic signaling in lithium-induced NDI at this VA facility opened an avenue for the development of better therapeutic modalities for the treatment of lithium-induced NDI. This grant application proposes studies to further strengthen these concepts.
描述(由申请人提供):
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
BELLAMKONDA K KISHORE其他文献
BELLAMKONDA K KISHORE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('BELLAMKONDA K KISHORE', 18)}}的其他基金
Targeting Renal Purinergic Signaling for the Treatment of Lithium-induced NDI
靶向肾脏嘌呤信号传导治疗锂诱导的 NDI
- 批准号:
8195888 - 财政年份:2010
- 资助金额:
-- - 项目类别:
Targeting Renal Purinergic Signaling for the Treatment of Lithium-induced NDI
靶向肾脏嘌呤信号传导治疗锂诱导的 NDI
- 批准号:
8397534 - 财政年份:2010
- 资助金额:
-- - 项目类别:
Targeting Renal Purinergic Signaling for the Treatment of Lithium-induced NDI
靶向肾脏嘌呤信号传导治疗锂诱导的 NDI
- 批准号:
8259070 - 财政年份:2010
- 资助金额:
-- - 项目类别:
Targeting Renal Purinergic Signaling for the Treatment of Lithium-induced NDI
靶向肾脏嘌呤信号传导治疗锂诱导的 NDI
- 批准号:
9907855 - 财政年份:2009
- 资助金额:
-- - 项目类别:
Potential Therapeutic Applications of Ecto-Nucleotidases in Lithium-induced NDI
外切核苷酸酶在锂诱导 NDI 中的潜在治疗应用
- 批准号:
7878061 - 财政年份:2009
- 资助金额:
-- - 项目类别:
Targeting Renal Purinergic Signaling for the Treatment of Lithium-induced NDI
靶向肾脏嘌呤信号传导治疗锂诱导的 NDI
- 批准号:
9339491 - 财政年份:2009
- 资助金额:
-- - 项目类别:
Targeting Renal Purinergic Signaling for the Treatment of Lithium-induced NDI
靶向肾脏嘌呤信号传导治疗锂诱导的 NDI
- 批准号:
8921910 - 财政年份:2009
- 资助金额:
-- - 项目类别:
Potential Therapeutic Applications of Ecto-Nucleotidases in Lithium-induced NDI
外切核苷酸酶在锂诱导 NDI 中的潜在治疗应用
- 批准号:
7660114 - 财政年份:2009
- 资助金额:
-- - 项目类别:
Targeting Renal Purinergic Signaling for the Treatment of Lithium-induced NDI
靶向肾脏嘌呤信号传导治疗锂诱导的 NDI
- 批准号:
9040769 - 财政年份:2009
- 资助金额:
-- - 项目类别:
P2U(P2Y2)-PURINOCEPTOR AND WATER TRANSPORT IN RAT KIDNEY
P2U(P2Y2)-嘌呤受体和大鼠肾脏中的水转运
- 批准号:
6517989 - 财政年份:2001
- 资助金额:
-- - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
-- - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
-- - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Downsides of downhill: The adverse effects of head vibration associated with downhill mountain biking on visuomotor and cognitive function
速降的缺点:与速降山地自行车相关的头部振动对视觉运动和认知功能的不利影响
- 批准号:
2706416 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Studentship














{{item.name}}会员




